Ryan Smith
Research Subjects
Ryan Smith has a total of 196 co-authors. Here are the top co-authors by number of shared publications:
- Varun Bhamidipati Dwaraka
TruDiagnostic, Inc., Lexington, KY, USA
13 shared publications Varun B. Dwaraka
TruDiagnostic, Lexington, USA
6 shared publications- Jessica Lasky-Su
Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, USA
5 shared publications Kirsten Seale
TruDiagnostic, 881 Corporate Drive, Lexington Kentucky
4 shared publications- Michael Jay Corley
University of California, San Diego, La Jolla, USA
4 shared publications Natalia Carreras-Gallo
TruDiagnostic, Lexington, KY, USA
4 shared publications
Latest Publications
- Open Access
- 21 August 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (9) , 3477-3490
Responsiveness of epigenetic aging biomarkers to longevity interventions in humans
Aging biomarkers can potentially allow researchers to rapidly monitor the impact of an aging intervention without the need for decade-spanning trials. However, before the use of aging biomarkers, such as epigenetic clocks, as surrogate endpoints, their responsiveness to interventions that target aging must be tested. Here we curate TranslAGE, a harmonized database of 51 public and private longitudinal interventional studies, and calculate a consistent set of 16 prominent epigenetic clocks for each study, along with 94 other DNA methylation (DNAm) biomarkers that can help explain the changes observed for each clock. Using this database, we discover patterns of responsiveness across a variety of interventions and DNAm biomarkers. For example, clocks trained to predict mortality or pace of aging show the strongest responses across all interventions and show consistent results with one another; pharmacological and lifestyle interventions drive the strongest responses from DNAm biomarkers; and the characteristics of the study population and study duration are key factors in determining the responsiveness of DNAm biomarkers to an intervention. Moreover, clocks with multiple subscores (that is ‘explainable clocks’) provide specificity and greater mechanistic insight into the responsiveness of interventions than single-score clocks. These findings can help to design future clinical trials by guiding the choice of interventions and of specific subsets of DNAm biomarkers to minimize multiple testing, study duration, study population and sample size, with the eventual aim of uncovering DNAm biomarkers that can be used as surrogate aging endpoints.
- 21 August 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (9) , 3477-3490
Open AccessResponsiveness of epigenetic aging biomarkers to longevity interventions in humans
Aging biomarkers can potentially allow researchers to rapidly monitor the impact of an aging intervention without the need for decade-spanning trials. However, before the use of aging biomarkers, such as epigenetic clocks, as surrogate endpoints, their responsiveness to interventions that target aging must be tested. Here we curate TranslAGE, a harmonized database of 51 public and private longitudinal interventional studies, and calculate a consistent set of 16 prominent epigenetic clocks for each study, along with 94 other DNA methylation (DNAm) biomarkers that can help explain the changes observed for each clock. Using this database, we discover patterns of responsiveness across a variety of interventions and DNAm biomarkers. For example, clocks trained to predict mortality or pace of aging show the strongest responses across all interventions and show consistent results with one another; pharmacological and lifestyle interventions drive the strongest responses from DNAm biomarkers; and the characteristics of the study population and study duration are key factors in determining the responsiveness of DNAm biomarkers to an intervention. Moreover, clocks with multiple subscores (that is ‘explainable clocks’) provide specificity and greater mechanistic insight into the responsiveness of interventions than single-score clocks. These findings can help to design future clinical trials by guiding the choice of interventions and of specific subsets of DNAm biomarkers to minimize multiple testing, study duration, study population and sample size, with the eventual aim of uncovering DNAm biomarkers that can be used as surrogate aging endpoints.
- Open Access
Regulatory mode and enhancer architecture determine limits of blood DNA methylation as a molecular proxy
Blood-based DNA methylation is widely used as a molecular surrogate for traits ranging from circulating protein and metabolite levels to biological aging, but whether the CpGs driving these models reflect genuine gene regulation or statistical convenience is unresolved. Training elastic-net models using the expression of 77 T cell genes across 333 matched T-cell enriched blood samples, we show that predictability is governed by regulatory mode: genes associated with differentiation and lineage-identity are strongly predictable, whereas dynamically regulated genes encoding cytokines and immune checkpoint ligands are not. The predictive CpGs are neither at the gene promoter nor at master-regulator binding sites; instead, the signal is carried by gene-specific sets of distal CpGs enriched within T-cell enhancer chromatin states distributed throughout the genome. Methylation-predicted gene expression validated against directly measured NanoString values in an independent 228-sample cancer cohort, remaining highly concordant for lineage genes but only weakly concordant for stimulus-responsive checkpoint ligands, confirming the lineage-versus-stimulus divide independently of the training cohort. On-gene retraining and chromatin-state annotation provide complementary tests of the genomic context of predictive CpGs.
Open AccessRegulatory mode and enhancer architecture determine limits of blood DNA methylation as a molecular proxy
Blood-based DNA methylation is widely used as a molecular surrogate for traits ranging from circulating protein and metabolite levels to biological aging, but whether the CpGs driving these models reflect genuine gene regulation or statistical convenience is unresolved. Training elastic-net models using the expression of 77 T cell genes across 333 matched T-cell enriched blood samples, we show that predictability is governed by regulatory mode: genes associated with differentiation and lineage-identity are strongly predictable, whereas dynamically regulated genes encoding cytokines and immune checkpoint ligands are not. The predictive CpGs are neither at the gene promoter nor at master-regulator binding sites; instead, the signal is carried by gene-specific sets of distal CpGs enriched within T-cell enhancer chromatin states distributed throughout the genome. Methylation-predicted gene expression validated against directly measured NanoString values in an independent 228-sample cancer cohort, remaining highly concordant for lineage genes but only weakly concordant for stimulus-responsive checkpoint ligands, confirming the lineage-versus-stimulus divide independently of the training cohort. On-gene retraining and chromatin-state annotation provide complementary tests of the genomic context of predictive CpGs.
- Open Access
- 11 July 2026
- Published by Springer Nature in Translational Psychiatry
- Vol. 16 (1)
Brain-targeted epigenetic effects of two emerging psychoplastogens: ketamine & MDMA
Psychoplastogen compounds such as ketamine and MDMA have shown therapeutic promise for mood and trauma-related disorders, yet the molecular mechanisms underlying their effects remain poorly understood. Here, we applied a Brain-Epigenome-Wide Association Study (BEWAS) targeting brain-relevant genes to examine DNA methylation changes following treatment. Pre- and post-treatment blood (ketamine, N = 20) and saliva (MDMA, N = 16) samples were collected from clinical trial participants. Treatment effects were assessed using repeated-measures linear mixed-effects models accounting for inter-individual baseline methylation differences, followed by gene- and network-level analyses. Ketamine and MDMA were associated with 405 and 346 significantly altered genes, respectively, alongside enrichment of 169 and 183 functional networks. Across both compounds, altered loci converged on pathways related to neuroplasticity and neuroimmune regulation. Together, these findings provide evidence that ketamine and MDMA induce peripheral epigenetic changes, highlighting their capacity to engage molecular pathways relevant to psychiatric health.
- 11 July 2026
- Published by Springer Nature in Translational Psychiatry
- Vol. 16 (1)
Open AccessBrain-targeted epigenetic effects of two emerging psychoplastogens: ketamine & MDMA
Psychoplastogen compounds such as ketamine and MDMA have shown therapeutic promise for mood and trauma-related disorders, yet the molecular mechanisms underlying their effects remain poorly understood. Here, we applied a Brain-Epigenome-Wide Association Study (BEWAS) targeting brain-relevant genes to examine DNA methylation changes following treatment. Pre- and post-treatment blood (ketamine, N = 20) and saliva (MDMA, N = 16) samples were collected from clinical trial participants. Treatment effects were assessed using repeated-measures linear mixed-effects models accounting for inter-individual baseline methylation differences, followed by gene- and network-level analyses. Ketamine and MDMA were associated with 405 and 346 significantly altered genes, respectively, alongside enrichment of 169 and 183 functional networks. Across both compounds, altered loci converged on pathways related to neuroplasticity and neuroimmune regulation. Together, these findings provide evidence that ketamine and MDMA induce peripheral epigenetic changes, highlighting their capacity to engage molecular pathways relevant to psychiatric health.
- Open Access
- 1 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Methylome-wide association study in blood suggests cell type-specific relationships between DNA methylation and lifetime anxiety
Anxiety disorders are prevalent and can greatly impact well-being. The biological mechanisms behind anxiety are not fully understood, but growing evidence suggests a role for DNA methylation. Here, we conduct a large-scale methylome-wide association study of lifetime anxiety in 14,443 participants (1817 cases and 12,626 controls) in whole blood, and, through epigenomic deconvolution, 12 different blood cell types. We detect four CpG associations at methylome-wide significance in whole blood, and a range between 15 and 124 associations among the cell types. Top cell type-specific findings include genes potentially involved in stress response such as FAM171A2 and VIPAS39 and genes that have been previously linked to anxiety, such as NCOR1. Whole blood and all cell type-specific findings significantly overlap with findings from two previous methylome-wide association studies of lifetime anxiety and an anxiety GWAS, suggesting results are robust. Pathway analyses broadly implicate anxiety-related impacts on cellular stress response. Analyses of five epigenetic clocks suggest DNA methylation-based phenotypic aging and pace of aging may be accelerated in anxiety. Our results support a cell type-specific relationship between DNA methylation and anxiety and highlight the utility of including cell type-specific analyses in whole blood studies of DNA methylation.
- 1 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessMethylome-wide association study in blood suggests cell type-specific relationships between DNA methylation and lifetime anxiety
Anxiety disorders are prevalent and can greatly impact well-being. The biological mechanisms behind anxiety are not fully understood, but growing evidence suggests a role for DNA methylation. Here, we conduct a large-scale methylome-wide association study of lifetime anxiety in 14,443 participants (1817 cases and 12,626 controls) in whole blood, and, through epigenomic deconvolution, 12 different blood cell types. We detect four CpG associations at methylome-wide significance in whole blood, and a range between 15 and 124 associations among the cell types. Top cell type-specific findings include genes potentially involved in stress response such as FAM171A2 and VIPAS39 and genes that have been previously linked to anxiety, such as NCOR1. Whole blood and all cell type-specific findings significantly overlap with findings from two previous methylome-wide association studies of lifetime anxiety and an anxiety GWAS, suggesting results are robust. Pathway analyses broadly implicate anxiety-related impacts on cellular stress response. Analyses of five epigenetic clocks suggest DNA methylation-based phenotypic aging and pace of aging may be accelerated in anxiety. Our results support a cell type-specific relationship between DNA methylation and anxiety and highlight the utility of including cell type-specific analyses in whole blood studies of DNA methylation.
- Top Cited PapersOpen Access
- 19 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Semaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy
Glucagon-like peptide-1 (GLP-1) receptor agonists have attracted interest as gerotherapeutics, yet clinical-trial evidence for their effects on biological aging is lacking. We report a post hoc exploratory epigenetic age analysis of a 32-week, randomized, double-blind, placebo-controlled phase 2b trial (NCT04019197) of semaglutide in adults with human immunodeficiency virus (HIV)-associated lipohypertrophy (semaglutide n = 45; placebo n = 39). The parent trial’s primary endpoint was change in visceral adipose tissue, with secondary cardiometabolic and body-composition endpoints; epigenetic aging was not pre-specified. To address this gap, we profiled peripheral-blood DNA methylation (DNAm) at baseline and week 32 to assess semaglutide versus placebo on first-, second-, and third-generation epigenetic aging measures. In adjusted analyses, semaglutide reduced epigenetic aging across multiple second- and third-generation clocks, including PhenoAge ( − 4.9 years/year, p = 0.004), PCGrimAge ( − 3.1, p = 0.007), GrimAge V2 ( − 2.3, p = 0.009), OMICmAge ( − 2.2, p = 0.009), RetroAge ( − 2.2, p = 0.030), and DunedinPACE ( − 0.09 units, 9% slower, p = 0.01). Systems-based clocks showed parallel reductions in inflammation, brain, and heart aging measures. The post hoc design, modest sample size, HIV-specific cohort, and 32-week follow-up limit generalizability. Prospective trials are needed to determine whether GLP-1 receptor agonists can be repurposed as gerotherapeutics.
- 19 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Top Cited PapersOpen AccessSemaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy
Glucagon-like peptide-1 (GLP-1) receptor agonists have attracted interest as gerotherapeutics, yet clinical-trial evidence for their effects on biological aging is lacking. We report a post hoc exploratory epigenetic age analysis of a 32-week, randomized, double-blind, placebo-controlled phase 2b trial (NCT04019197) of semaglutide in adults with human immunodeficiency virus (HIV)-associated lipohypertrophy (semaglutide n = 45; placebo n = 39). The parent trial’s primary endpoint was change in visceral adipose tissue, with secondary cardiometabolic and body-composition endpoints; epigenetic aging was not pre-specified. To address this gap, we profiled peripheral-blood DNA methylation (DNAm) at baseline and week 32 to assess semaglutide versus placebo on first-, second-, and third-generation epigenetic aging measures. In adjusted analyses, semaglutide reduced epigenetic aging across multiple second- and third-generation clocks, including PhenoAge ( − 4.9 years/year, p = 0.004), PCGrimAge ( − 3.1, p = 0.007), GrimAge V2 ( − 2.3, p = 0.009), OMICmAge ( − 2.2, p = 0.009), RetroAge ( − 2.2, p = 0.030), and DunedinPACE ( − 0.09 units, 9% slower, p = 0.01). Systems-based clocks showed parallel reductions in inflammation, brain, and heart aging measures. The post hoc design, modest sample size, HIV-specific cohort, and 32-week follow-up limit generalizability. Prospective trials are needed to determine whether GLP-1 receptor agonists can be repurposed as gerotherapeutics.
- Open Access
The Epigenetic Fingerprint of Lifestyle: Smoking, Vaping, and Exercise Revealed Through Buccal DNA Methylation
Background/Objectives: Lifestyle behaviors such as smoking, vaping, and physical activity can induce epigenetic modifications that influence health trajectories and may provide forensic value. DNA methylation signatures linked to these behaviors offer potential for behavioral inference, personalized health assessment, and improved investigative practices. This study aimed to characterize methylation patterns associated with nicotine exposure and exercise using buccal cell DNA profiling, and to evaluate the extent to which these patterns differentiate harmful and protective lifestyle habits. Methods: Buccal epithelial DNA was analyzed using the Illumina Infinium MethylationEPIC v2 BeadChip to assess genome-wide methylation. Participants were categorized by smoking status, vaping behavior, and exercise activity. Differentially methylated regions (DMRs) and CpG sites were identified through pairwise comparisons among smokers, vapers, non-smokers/non-vapers, athletes, and sedentary individuals. A threshold of p < 1 × 10−4 was applied for significant differentially methylated CpG sites. Results: Distinct epigenetic profiles were associated with smoking/vaping and physical activity. Five DMRs differentiated smokers from non-smokers/non vapers, while 11 DMRs distinguished vapers from the same reference group. Twenty-eight DMRs displayed divergent methylation patterns between smokers and vapers. Exercise also showed measurable epigenetic influence: control athletes exhibited 26 significantly differentially methylated CpG sites relative to non-athletes, and smoker athletes demonstrated 126 suggestive differential sites compared to sedentary smokers. Additionally, 63 sites differentiated smoker athletes from non-smoker/non-vaper non-athletes, indicating interactions between risk-associated and health-promoting behaviors. Conclusions: Buccal cell DNA methylation profiling effectively captured signatures associated with smoking, vaping, and physical activity. These findings underscore the potential of epigenetic markers for lifestyle assessment in both personalized medicine and forensic investigations.
Open AccessThe Epigenetic Fingerprint of Lifestyle: Smoking, Vaping, and Exercise Revealed Through Buccal DNA Methylation
Background/Objectives: Lifestyle behaviors such as smoking, vaping, and physical activity can induce epigenetic modifications that influence health trajectories and may provide forensic value. DNA methylation signatures linked to these behaviors offer potential for behavioral inference, personalized health assessment, and improved investigative practices. This study aimed to characterize methylation patterns associated with nicotine exposure and exercise using buccal cell DNA profiling, and to evaluate the extent to which these patterns differentiate harmful and protective lifestyle habits. Methods: Buccal epithelial DNA was analyzed using the Illumina Infinium MethylationEPIC v2 BeadChip to assess genome-wide methylation. Participants were categorized by smoking status, vaping behavior, and exercise activity. Differentially methylated regions (DMRs) and CpG sites were identified through pairwise comparisons among smokers, vapers, non-smokers/non-vapers, athletes, and sedentary individuals. A threshold of p < 1 × 10−4 was applied for significant differentially methylated CpG sites. Results: Distinct epigenetic profiles were associated with smoking/vaping and physical activity. Five DMRs differentiated smokers from non-smokers/non vapers, while 11 DMRs distinguished vapers from the same reference group. Twenty-eight DMRs displayed divergent methylation patterns between smokers and vapers. Exercise also showed measurable epigenetic influence: control athletes exhibited 26 significantly differentially methylated CpG sites relative to non-athletes, and smoker athletes demonstrated 126 suggestive differential sites compared to sedentary smokers. Additionally, 63 sites differentiated smoker athletes from non-smoker/non-vaper non-athletes, indicating interactions between risk-associated and health-promoting behaviors. Conclusions: Buccal cell DNA methylation profiling effectively captured signatures associated with smoking, vaping, and physical activity. These findings underscore the potential of epigenetic markers for lifestyle assessment in both personalized medicine and forensic investigations.
- Open Access
- 19 March 2026
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 46, 102546
Non-linear age-related change in human Interleukin-11 and the receptor subunit alpha DNA methylation
- 19 March 2026
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 46, 102546
Open AccessNon-linear age-related change in human Interleukin-11 and the receptor subunit alpha DNA methylation
- Open Access
Skin DNA Methylation Encodes Multidimensional Facial Aging Phenotypes with Distinct Biological Architectures
Whether distinct visible aging traits, e.g., wrinkling, pigmentation, and inflammation, reflect shared or independent epigenetic programs remains unknown; existing clocks compress aging into a single chronological axis, leaving the phenotype-specific architecture of cutaneous aging uncharacterized. Here, we integrate AI-derived facial phenotypes with skin DNA methylation profiles from 706 individuals to develop EpiVision, a panel of 21 epigenetic predictors spanning structural, pigmentary, inflammatory, and textural aging traits. Predictors reveal shared and trait-specific pathways, including developmental patterning, epithelial remodeling, hormonal signaling, and UV damage responses, and capture environmentally induced acceleration in sun-exposed skin alongside lifestyle and topical treatment–associated variation. These findings establish that visible skin aging comprises molecularly distinct axes with shared regulatory substrates and trait-specific drivers, providing a scalable epigenetic framework for intervention evaluation and aging biology research.
Open AccessSkin DNA Methylation Encodes Multidimensional Facial Aging Phenotypes with Distinct Biological Architectures
Whether distinct visible aging traits, e.g., wrinkling, pigmentation, and inflammation, reflect shared or independent epigenetic programs remains unknown; existing clocks compress aging into a single chronological axis, leaving the phenotype-specific architecture of cutaneous aging uncharacterized. Here, we integrate AI-derived facial phenotypes with skin DNA methylation profiles from 706 individuals to develop EpiVision, a panel of 21 epigenetic predictors spanning structural, pigmentary, inflammatory, and textural aging traits. Predictors reveal shared and trait-specific pathways, including developmental patterning, epithelial remodeling, hormonal signaling, and UV damage responses, and capture environmentally induced acceleration in sun-exposed skin alongside lifestyle and topical treatment–associated variation. These findings establish that visible skin aging comprises molecularly distinct axes with shared regulatory substrates and trait-specific drivers, providing a scalable epigenetic framework for intervention evaluation and aging biology research.
- Open Access
- 13 March 2026
- Published by Springer Nature in Research Square
Plasticity of X-chromosome inactivation in female reproduction
X-chromosome inactivation (XCI) is a mammalian mechanism for dosage compensation, yet its dynamics across reproductive states remain poorly characterized. Here we identify XCI plasticity in female reproductive tissues, including the endometrium and maternal immune cells. Single-cell transcriptomic analyses show that proliferating endometrial stromal cells exhibit the highest silenced-to-escape expression ratio (STER)—a relative measure of expression balance between XCI-silenced and canonical escape X-linked genes—accompanied by reduced allelic imbalance of silenced genes, before sharply declining during decidualization. In contrast, maternal immune cells maintain a low STER with increased XIST expression across gestation. Epigenetic profiling reveals increased biallelic demethylation of silenced genes during endometrial proliferation. This biallelic demethylation is reduced in maternal blood during healthy gestation but increased in complicated pregnancies and in nulliparous women. Cross-species analyses reveal similar XCI plasticity in subfertile cattle and strong correlations between baseline XCI dynamics and lifetime reproductive potential across mammals. Together, these findings establish XCI plasticity as a dynamic feature of mammalian reproduction.
- 13 March 2026
- Published by Springer Nature in Research Square
Open AccessPlasticity of X-chromosome inactivation in female reproduction
X-chromosome inactivation (XCI) is a mammalian mechanism for dosage compensation, yet its dynamics across reproductive states remain poorly characterized. Here we identify XCI plasticity in female reproductive tissues, including the endometrium and maternal immune cells. Single-cell transcriptomic analyses show that proliferating endometrial stromal cells exhibit the highest silenced-to-escape expression ratio (STER)—a relative measure of expression balance between XCI-silenced and canonical escape X-linked genes—accompanied by reduced allelic imbalance of silenced genes, before sharply declining during decidualization. In contrast, maternal immune cells maintain a low STER with increased XIST expression across gestation. Epigenetic profiling reveals increased biallelic demethylation of silenced genes during endometrial proliferation. This biallelic demethylation is reduced in maternal blood during healthy gestation but increased in complicated pregnancies and in nulliparous women. Cross-species analyses reveal similar XCI plasticity in subfertile cattle and strong correlations between baseline XCI dynamics and lifetime reproductive potential across mammals. Together, these findings establish XCI plasticity as a dynamic feature of mammalian reproduction.
- Top Cited PapersOpen Access
- 25 February 2026
- Published by Springer Nature in Nature Aging
- Vol. 6 (3) , 722-737
OMICmAge quantifies biological age by integrating multi-omics with electronic medical records
Biological aging reflects complex cellular and biochemical processes that can be measured across multiple omic layers. Using routine clinical laboratory data from ~31,000 participants in the Mass General Brigham Biobank, we developed EMRAge, a biomarker of mortality risk that can be broadly recapitulated across electronic medical records. Here we show that EMRAge can be modeled using elastic net regression with DNA methylation and multi-omics to generate DNAmEMRAge and OMICmAge, respectively. Both biomarkers are strongly associated with incident and prevalent chronic diseases and mortality, performing comparably or better than current biomarkers across discovery (Massachusetts General Brigham Aging Biobank Cohort, n = 3,451) and validation cohorts (TruDiagnostic, n = 14,213; Generation Scotland, n = 18,672). Importantly, OMICmAge leverages epigenetic biomarker proxies to integrate proteomic, metabolomic and clinical domains while remaining quantifiable from DNA methylation alone. This framework establishes an accessible, scalable measure of biological aging with potential to reveal molecular interconnections that shape healthspan and disease risk.
- 25 February 2026
- Published by Springer Nature in Nature Aging
- Vol. 6 (3) , 722-737
Top Cited PapersOpen AccessOMICmAge quantifies biological age by integrating multi-omics with electronic medical records
Biological aging reflects complex cellular and biochemical processes that can be measured across multiple omic layers. Using routine clinical laboratory data from ~31,000 participants in the Mass General Brigham Biobank, we developed EMRAge, a biomarker of mortality risk that can be broadly recapitulated across electronic medical records. Here we show that EMRAge can be modeled using elastic net regression with DNA methylation and multi-omics to generate DNAmEMRAge and OMICmAge, respectively. Both biomarkers are strongly associated with incident and prevalent chronic diseases and mortality, performing comparably or better than current biomarkers across discovery (Massachusetts General Brigham Aging Biobank Cohort, n = 3,451) and validation cohorts (TruDiagnostic, n = 14,213; Generation Scotland, n = 18,672). Importantly, OMICmAge leverages epigenetic biomarker proxies to integrate proteomic, metabolomic and clinical domains while remaining quantifiable from DNA methylation alone. This framework establishes an accessible, scalable measure of biological aging with potential to reveal molecular interconnections that shape healthspan and disease risk.